A guaiane sesquiterpene lactone compound, a chrysanthemum indicum extract, and a preparation method and application thereof
By extracting and preparing guaiacane-type sesquiterpene lactones and their extracts from wild chrysanthemum, the limitations of wild chrysanthemum in the treatment of inflammatory diseases caused by NF-κB nuclear translocation were addressed, achieving significant inhibitory and anti-inflammatory effects on NF-κB nuclear translocation.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- GUANGZHOU UNIVERSITY OF CHINESE MEDICINE
- Filing Date
- 2023-11-30
- Publication Date
- 2026-06-02
AI Technical Summary
No existing research reports on whether wild chrysanthemum and its active ingredients have an inhibitory effect on NF-κB nuclear translocation, which limits its application in the treatment of inflammatory diseases caused by NF-κB nuclear translocation.
A novel guaiacane-type sesquiterpene lactone compound and its extract were extracted and prepared from wild chrysanthemum. The active ingredients were enriched by specific solvents and liquid chromatography elution methods, and the compound and extract with significant inhibitory effect on NF-κB nuclear translocation were prepared.
It achieved a significant inhibitory effect on NF-κB nuclear translocation, providing a new anti-inflammatory drug component for the treatment of inflammatory diseases caused by NF-κB nuclear translocation, with significantly better efficacy than the existing drug dexamethasone.
Smart Images
Figure CN117903156B_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of pharmaceutical chemistry, specifically to a guaiacol-type sesquiterpene lactone compound, a wild chrysanthemum extract, its preparation method, and its application. Background Technology
[0002] Wild chrysanthemum, the dried aerial parts of *Chrysanthemumindicum* L. (family Asteraceae), is also known as malaria herb, bitter chrysanthemum, and roadside yellow chrysanthemum. Wild chrysanthemum resources are abundant and widely distributed in my country. It is a commonly used traditional Chinese medicine; its stems, leaves, inflorescences, and the whole plant can all be used medicinally. It has a bitter and pungent taste, and is cold in nature. It possesses the effects of clearing heat and detoxifying, dispelling wind and heat, dispersing blood stasis, improving eyesight, and lowering blood pressure. Clinically, it has significant therapeutic effects in preventing and treating diseases such as prostatitis, chronic pelvic inflammatory disease, hepatitis, mumps, influenza, hypertension, and tuberculosis.
[0003] However, there are no research reports on whether existing technologies have an inhibitory effect on NF-κB nuclear translocation, including wild chrysanthemum and its effective parts and components. Summary of the Invention
[0004] In order to overcome at least one of the technical problems existing in the prior art, the present invention first provides a guaiacane-type sesquiterpene lactone compound and a wild chrysanthemum extract.
[0005] The technical problem to be solved by the present invention is achieved through the following technical solution:
[0006] This invention first provides a guaiacane-type sesquiterpene lactone compound having the structure shown in formula (I):
[0007]
[0008] This invention provides the first preparation of a novel guaiacol-type sesquiterpene lactone compound with the structure shown in Formula (I) from Chrysanthemum indicum extract. Further research by the inventors revealed that the guaiacol-type sesquiterpene lactone compound with the structure shown in Formula (I) exhibits a significant inhibitory effect on NF-κB nuclear translocation. Therefore, using the guaiacol-type sesquiterpene lactone compound with the structure shown in Formula (I) as an active ingredient in the preparation of drugs for treating inflammatory diseases caused by NF-κB nuclear translocation has significant application value.
[0009] The present invention also provides a method for preparing guaiacane-type sesquiterpene lactone compounds, which are prepared using wild chrysanthemum as raw material.
[0010] This invention provides a novel method for preparing guaiac alkyl sesquiterpene lactones, which for the first time prepares guaiac alkyl sesquiterpene lactones with the structure shown in formula (Ⅰ) from wild chrysanthemum.
[0011] The present invention also provides a wild chrysanthemum extract comprising a guaiac sesquiterpene lactone compound with the structure shown in formula (I).
[0012] This invention provides a wild chrysanthemum extract containing a guaiac sesquiterpene lactone compound with the structure shown in formula (I). Since the guaiac sesquiterpene lactone compound with the structure shown in formula (I) has a significant inhibitory effect on NF-κB nuclear translocation, it can be inferred that the wild chrysanthemum extract containing the guaiac sesquiterpene lactone compound with the structure shown in formula (I) also has an inhibitory effect on NF-κB nuclear translocation.
[0013] This invention also provides a method for preparing wild chrysanthemum extract, which includes the following steps:
[0014] (1) Take dried wild chrysanthemum stems and leaves and extract them with ethanol to obtain an extract. Concentrate and dry the extract to obtain a crude extract.
[0015] (2) Load the crude extract onto a silica gel column and elute it with an organic solvent consisting of petroleum ether and ethyl acetate in a volume ratio of 35-45:55-65 to obtain eluent A; then elute it with ethyl acetate to obtain eluent B; take eluent B, concentrate and dry it to obtain the eluted portion of Chrysanthemum indicum on silica gel column.
[0016] (3) The eluted portion of Chrysanthemum indicum was loaded onto an ODS column. First, it was eluted with a methanol aqueous solution with a volume fraction of 48-52% to remove impurities. Then, it was eluted with a methanol aqueous solution with a volume fraction of 58-62%. The eluent eluted with the methanol aqueous solution with a volume fraction of 58-62% was collected, concentrated and dried to obtain the eluted portion of Chrysanthemum indicum ODS.
[0017] The wild chrysanthemum extract was obtained by eluting the ODS fraction of wild chrysanthemum.
[0018] The inventors discovered in their research that the eluted fraction of wild chrysanthemum ODS prepared by the above method also has an inhibitory effect on NF-κB nuclear translocation.
[0019] Preferably, in step (1), the ratio of dried wild chrysanthemum stems and leaves to ethanol is 1 kg: 5-15 L;
[0020] The ethanol used is an aqueous solution of ethanol with a volume fraction of 70-95%.
[0021] Most preferably, the ratio of dried wild chrysanthemum stems and leaves to ethanol in step (1) is 1 kg: 10 L;
[0022] The ethanol used is an aqueous solution of ethanol with a volume fraction of 95%.
[0023] Most preferably, in step (2), the eluent is first eluted with an organic solvent consisting of petroleum ether and ethyl acetate in a volume ratio of 40:60 to obtain eluent A.
[0024] Preferably, in step (3), the impurities are first removed by elution with a 50% methanol aqueous solution; then, the impurities are removed by elution with a 60% methanol aqueous solution, and the eluent obtained by elution with a 60% methanol aqueous solution is collected.
[0025] Preferably, the ODS eluted fraction of wild chrysanthemum is further eluted by liquid chromatography to obtain wild chrysanthemum extract;
[0026] The liquid chromatography elution conditions were as follows: a reverse-phase column was used; 55% acetonitrile aqueous solution was used as the mobile phase; the flow rate was 5-15 mL / min; the detection wavelength was 220-250 nm; the eluent eluted over a period of 8.5-10.4 min was collected, concentrated, and dried to obtain wild chrysanthemum extract.
[0027] The inventors were surprised to find that the wild chrysanthemum extract prepared by further eluting the wild chrysanthemum ODS fraction under the above-mentioned liquid chromatography elution conditions had a significantly higher inhibitory effect on NF-κB nuclear translocation than the wild chrysanthemum ODS fraction.
[0028] In particular, its inhibitory effect on NF-κB nuclear translocation is significantly higher than that of guaiacol-type sesquiterpene lactones with the structure shown in formula (I) and the positive control drug dexamethasone, achieving an unexpected inhibitory effect on NF-κB nuclear translocation. This is because the above-mentioned liquid chromatography elution conditions can enrich a large number of active ingredients that inhibit NF-κB nuclear translocation, and these active ingredients can have a synergistic effect, thus resulting in a better inhibitory effect on NF-κB nuclear translocation.
[0029] The eluted fraction of Chrysanthemum indicum prepared by this method also inhibited NF-κB nuclear translocation.
[0030] The present invention also provides a wild chrysanthemum extract prepared by the above preparation method.
[0031] The present invention also provides the application of the above-mentioned guaiacol-type sesquiterpene lactone compound or wild chrysanthemum extract in the preparation of a drug having the effect of inhibiting NF-κB nuclear translocation.
[0032] The present invention also provides the use of the above-mentioned guaiacol-type sesquiterpene lactone compound or wild chrysanthemum extract in the preparation of a medicament for treating inflammatory diseases.
[0033] Preferably, the inflammatory disease is an inflammatory disease caused by NF-κB nuclear translocation.
[0034] The present invention also provides the application of the above-mentioned guaiacol-type sesquiterpene lactone compound or wild chrysanthemum extract in the preparation of a drug with anti-inflammatory effects.
[0035] Preferably, the anti-inflammatory effect refers to the anti-inflammatory effect caused by NF-κB nuclear translocation.
[0036] Beneficial Effects: This invention provides a novel guaiacane-type sesquiterpene lactone compound with the structure shown in Formula (I), and a wild chrysanthemum extract. Studies have shown that the guaiacane-type sesquiterpene lactone compound with the structure shown in Formula (I) and the wild chrysanthemum extract have significant inhibitory effects on NF-κB nuclear translocation. Therefore, further using the guaiacane-type sesquiterpene lactone compound with the structure shown in Formula (I) or the wild chrysanthemum extract as active ingredients in the preparation of anti-inflammatory drugs and drugs for treating inflammatory diseases caused by NF-κB nuclear translocation has important application value. Attached Figure Description
[0037] Figure 1 The compound described in this invention 1 H-NMR spectrum (400MHz).
[0038] Figure 2 The compound described in this invention 13 C-NMR spectrum (100MHz).
[0039] Figure 3 This is a DEPT-135 diagram of the compound described in this invention.
[0040] Figure 4 This is the COSY NMR spectrum of the compound described in this invention.
[0041] Figure 5 This is the HSQC NMR spectrum of the compound described in this invention.
[0042] Figure 6 This is the HMBC NMR spectrum of the compound described in this invention.
[0043] Figure 7 This is the NOESY NMR spectrum of the compound described in this invention.
[0044] Figure 8 This is the ECD diagram of the compound described in this invention. Detailed Implementation
[0045] The present invention will be further explained below with reference to specific embodiments, but the embodiments do not limit the present invention in any way.
[0046] Example 1: Preparation of guaiacol-type sesquiterpene lactones
[0047] (1) Take dried wild chrysanthemum stems and leaves, crush them, and extract them with ethanol at room temperature for 3 days to obtain an extract. Concentrate and dry the extract to obtain a crude extract. The ratio of dried wild chrysanthemum stems and leaves to ethanol is 1 kg: 10 L. The ethanol used is an aqueous solution with a volume fraction of 95%.
[0048] (2) Load the crude extract onto a silica gel column (the silica gel column is filled with 100-200 mesh silica gel, and the weight of the silica gel is 30 times the weight of the crude extract). First, elute with an organic solvent consisting of petroleum ether and ethyl acetate in a volume ratio of 40:60, which is 5 column volumes, to obtain eluent A. Then, elute with ethyl acetate, which is 5 column volumes, to obtain eluent B. Take eluent B, concentrate and dry it to obtain the chrysanthemum silica gel column elution fraction.
[0049] (3) The elution fraction of wild chrysanthemum on a silica gel column was loaded onto an ODS column (the weight of ODS in the silica gel column was 30 times the weight of the crude extract). First, it was eluted with 5 column volumes of 50% methanol aqueous solution to remove impurities. Then, it was eluted with 5 column volumes of 60% methanol aqueous solution. The eluent eluted with 60% methanol aqueous solution was collected, concentrated and dried to obtain the eluted fraction of wild chrysanthemum ODS.
[0050] (4) The ODS elution fraction of wild chrysanthemum was further eluted by liquid chromatography to obtain the guaiac alkyl sesquiterpene lactone compound described in this invention.
[0051] The liquid chromatography elution conditions are as follows: a COSMOSIL 5μm (4.6×150mm Column) column is used; 55% acetonitrile aqueous solution is used as the mobile phase, the flow rate is 10mL / min, and the detection wavelength is 235nm; the eluent corresponding to the chromatographic peak at 9.6min is collected, concentrated and dried to obtain the guaiacol-type sesquiterpene lactone compound of the present invention.
[0052] Identification of compounds:
[0053] The obtained compound was a colorless oil. TLC identification was performed using dichloromethane-methanol (16:1) as the developing solvent. f =0.5, vanillin-concentrated sulfuric acid as a colorimetric reagent turns blue upon heating at 105℃. See also Figures 1-5 The IR spectrum shows that the molecule contains hydroxyl groups (3488 cm⁻¹). -1 ), carbonyl (1749cm) -1 ) and double bonds (1454cm) -1 Functional groups. High-resolution mass spectrometry gives the molecular formula C 35 H42 O8, [M+Na] + 613.2822, unsaturation degree is 15. In 1 In H-NMR spectra, the typical two methyl proton signals δ H 1.93(3H,dd,J=1.2,7.6Hz,4″-CH3), δ H 1.85 (3H,s,5″-CH3) and a double bond proton signal δ H 6.11(1H,m,H-3″), combined with 13 C-NMR spectral signal δ C 166.7 (C-1″), δ C 127.4 (C-2″), δ C 141.6(C-3″), δ C 16.2(C-4″), δ C 20.6 (C-5″) indicates that the compound contains an angelic acyl group. Two sets of double bond signals: δ H 5.93 (1H, s, H-3), δ C 134.6 (C-3), δ C 177.4 (C-4), δ H 6.08(1H,d,J=5.2Hz,H-2′), δ H 5.94 (1H, m, H-3′), δ C 139.6(C-2′), δ C 131.6(C-3′); A set of α,β-unsaturated lactone fragment signals: δ H 6.05(1H,d,J=3.2Hz,H-13′a), δ H 5.33(1H,d,J=3.2Hz,H-13′b), δ C 141.0(C-11′), δ C 170.3 (C-12′), δ C 118.7 (C-13′); Proton signal δ of two triplet peaks H 3.81 (1H,t,J=9.6Hz), δ H 3.12 (1H,t,J=9.6Hz) and two methylene hydrogen proton signals δ H 4.07 (1H,t,J=9.6Hz), δ H 3.01 (1H, m); δ H 6.08(1H,d,J=5.2Hz,H-2′), δ H5.94 (1H, m, H-3′) represents an intracyclic double bond. The above data suggests that this compound may be a guaiacol-type sesquiterpene dimer.
[0054] See Figure 6 HMBC spectrum shows δ H 6.08(H-2′), δ H 5.94(H-3′), δ H 1.48(H-15′) are both related to δ C 59.8(C-11) has long-range correlation, δ H 6.08(H-2′), δ H 5.94(H-3′), δ H 2.34(H-13) are all related to δ C 65.0 (C-1′) shows a long-range correlation, suggesting that the two guaiacol-type sesquiterpene moieties are linked through C-13 to C-1′ and C-11 to C-4′ to form a dimer; δ H 2.86 (H-1), δ H 5.94 (H-3), δ H 3.02(H-5) are all related to δ C 207.5 (C-2) shows a long-range correlation, indicating that a carbonyl group is attached at the C-2 position; δ H 2.86 (H-1), δ H 5.41(H-8), δ H 1.37(H-14) are all related to δ C 26.9 (C-10) has a long-range correlation, indicating that a methyl group is attached at the C-10 position.
[0055] See Figure 7 The NOESY spectrum shows H-5 / H-1, H-7, H-6 / H-8, H-14, H-8 / H-13, H-15′ / H-6′, H-14′ / H-15′, and H-5′ / H-7′. This indicates that H-1, H-5, H-7, H-5′, and H-7′ are α-oriented, while H-6, H-8, H-14, H-6′, H-14′, and H-15′ are β-oriented.
[0056] See Figure 8 The ECD spectrum showed similarity to the theoretically calculated ECD spectrum of (1S,5R,6R,7R,8S,10S,11R,1′R,4′R,5′S,6′S,7′S,10′R)I, thus confirming the absolute configuration of the compound as (1S,5R,6R,7R,8S,10S,11R,1′R,4′R,5′S,6′S,7′S,10′R).
[0057] In summary, the guaiacol-type sesquiterpene lactone compounds of this invention are identified as having the structure shown in formula (Ⅰ).
[0058] Table 1. Compounds of the present invention 1 H NMR and 13 C10 NMR data (CDCl3, J = Hz)
[0059]
[0060]
[0061] Example 2: Preparation of Wild Chrysanthemum Extract
[0062] (1) Take dried wild chrysanthemum stems and leaves, crush them, and extract them with ethanol at room temperature for 3 days to obtain an extract. Concentrate and dry the extract to obtain a crude extract. The ratio of dried wild chrysanthemum stems and leaves to ethanol is 1 kg: 10 L. The ethanol used is an aqueous solution with a volume fraction of 95%.
[0063] (2) Load the crude extract onto a silica gel column (the silica gel column is filled with 100-200 mesh silica gel, and the weight of the silica gel is 30 times the weight of the crude extract). First, elute with an organic solvent consisting of petroleum ether and ethyl acetate in a volume ratio of 40:60, which is 5 column volumes, to obtain eluent A. Then, elute with ethyl acetate, which is 5 column volumes, to obtain eluent B. Take eluent B, concentrate and dry it to obtain the chrysanthemum silica gel column elution fraction.
[0064] (3) The elution fraction of wild chrysanthemum on a silica gel column was loaded onto an ODS column (the weight of ODS in the silica gel column was 30 times the weight of the crude extract). First, it was eluted with 5 column volumes of 50% methanol aqueous solution to remove impurities. Then, it was eluted with 5 column volumes of 60% methanol aqueous solution. The eluent eluted with 60% methanol aqueous solution was collected, concentrated and dried to obtain the eluted fraction of wild chrysanthemum ODS.
[0065] The wild chrysanthemum extract was obtained by eluting the ODS fraction of wild chrysanthemum.
[0066] Example 3: Preparation of Wild Chrysanthemum Extract
[0067] (1) Take dried wild chrysanthemum stems and leaves, crush them, and extract them with ethanol at room temperature for 3 days to obtain an extract. Concentrate and dry the extract to obtain a crude extract. The ratio of dried wild chrysanthemum stems and leaves to ethanol is 1 kg: 10 L. The ethanol used is an aqueous solution with a volume fraction of 95%.
[0068] (2) Load the crude extract onto a silica gel column (the silica gel column is filled with 100-200 mesh silica gel, and the weight of the silica gel is 30 times the weight of the crude extract). First, elute with an organic solvent consisting of petroleum ether and ethyl acetate in a volume ratio of 40:60, which is 5 column volumes, to obtain eluent A. Then, elute with ethyl acetate, which is 5 column volumes, to obtain eluent B. Take eluent B, concentrate and dry it to obtain the chrysanthemum silica gel column elution fraction.
[0069] (3) The elution fraction of wild chrysanthemum on a silica gel column was loaded onto an ODS column (the weight of ODS in the silica gel column was 30 times the weight of the crude extract). First, it was eluted with 5 column volumes of 50% methanol aqueous solution to remove impurities. Then, it was eluted with 5 column volumes of 60% methanol aqueous solution. The eluent eluted with 60% methanol aqueous solution was collected, concentrated and dried to obtain the eluted fraction of wild chrysanthemum ODS.
[0070] (4) The ODS elution fraction of wild chrysanthemum was further eluted by liquid chromatography to obtain wild chrysanthemum extract;
[0071] The liquid chromatography elution conditions were as follows: a COSMOSIL 5μm (4.6×150mm Column) column was used; 55% acetonitrile aqueous solution was used as the mobile phase; the flow rate was 10mL / min; and the detection wavelength was 235nm. The eluent eluted over a period of 8.5–10.4 min was collected, concentrated, and dried to obtain the wild chrysanthemum extract.
[0072] Comparative Example 1: Preparation of Wild Chrysanthemum Extract
[0073] The preparation method of wild chrysanthemum extract in Comparative Example 1 is the same as that in Example 3, except that the elution conditions for liquid chromatography are different.
[0074] The liquid chromatography elution conditions were as follows: a COSMOSIL 5μm (4.6×150mm Column) column was used; 55% acetonitrile aqueous solution was used as the mobile phase; the flow rate was 10mL / min; and the detection wavelength was 235nm. The eluent eluted over a period of 12.0–14.5 min was collected, concentrated, and dried to obtain the wild chrysanthemum extract.
[0075] Comparative Example 2: Preparation of Wild Chrysanthemum Extract
[0076] The preparation method of wild chrysanthemum extract in Comparative Example 2 is the same as that in Example 3, except that the elution conditions for liquid chromatography are different.
[0077] The liquid chromatography elution conditions were as follows: a COSMOSIL 5μm (4.6×150mm Column) column was used; 45% acetonitrile aqueous solution was used as the mobile phase; the flow rate was 10mL / min; and the detection wavelength was 235nm. The eluent eluted over a period of 10.5–13.6 min was collected, concentrated, and dried to obtain the wild chrysanthemum extract.
[0078] Experimental Example
[0079] 1. Preparation of test samples: The test samples used are guaiac sesquiterpene lactone compounds with the structure shown in formula (Ⅰ), wild chrysanthemum extracts prepared in Examples 2 and 3 and Comparative Examples 1 and 2, and the positive control drug dexamethasone.
[0080] 2. RAW264.7 mouse macrophages were purchased from the US Standard Bacterial Bank, and resident peritoneal macrophages (RPMs) were obtained from SD rats provided by the University of Hong Kong. Cells were preserved in a medium containing 10% FBS, 100 units / ml penicillin G, 100 mg / ml streptomycin, and 2 mM L-L-glutamine, and cultured under saturated humidity, 37°C, and 5% CO2 conditions.
[0081] 3. The sample to be tested is dissolved in DMSO, with a stock solution concentration of 20 mg / ml and a working concentration of 10 mg / ml.
[0082] 4. RAW264.7 cells were cultured at a concentration of 1.0 × 10⁻⁶. 4 pcs / hole and 0.3×10 4 Cells were cultured in 96-well plates at a density of 18 h, pretreated with test samples for 6 h and 1 h, respectively, and then treated with 200 ng / ml LPS for 40 min and 18 h. The test sample for experimental group 1 was a guaiacol-type sesquiterpene lactone compound with the structure shown in formula (Ⅰ); the test samples for experimental groups 2–5 were wild chrysanthemum extracts prepared in Examples 2 and 3, and Comparative Examples 1 and 2; the test sample for the positive control group was dexamethasone. A blank group (no drug administration) and a normal group were also included.
[0083] 5. Measurement of NF-κB nuclear transport: RAW264.7 cells were subjected to a concentration of 1.0 × 10⁻⁶ cells / mL. 4Cells were seeded in 96-well plates and cultured for 18 h. Cells were then pretreated for 1 h with the test sample at a concentration of 10 mg / mL and DMSO (0.01%). Next, cells were treated for 40 min with solutions containing 200 ng / mL LPS and without LPS, respectively. Cells were fixed with 4% PFA for 15 min, infiltrated with 0.2% Trition-100X for 15 min, blocked with 3% BSA for 0.5 h, stained with p65 antibody (1:500 dilution) for 3 h, and cultured with DAPI for 5 min. Finally, the cells were plate-imaged, and NF-κB nuclear translocations were analyzed by HCl.
[0084] 6. Statistical Analysis: All data were analyzed using nuclear translocation data from an HCS imager and Graph PadPrism 7.0 software. One-way ANOVA was used to compare the statistical significance of different compound treatment groups, and then the SNK method was used in Graph PadPrism 7.0 software for further analysis.
[0085] Table 1. Experimental results of the inhibition of nuclear translocation by the compounds of this invention and the extract of Chrysanthemum indicum.
[0086]
[0087] As can be seen from the experimental results in Table 1, the guaiacane-type sesquiterpene lactone compound with the structure shown in formula (Ⅰ) of the present invention has a significant inhibitory effect on NF-κB nuclear translocation; the wild chrysanthemum ODS elution fraction prepared by the method of the present invention in Example 2 also has an inhibitory effect on NF-κB nuclear translocation.
[0088] The experimental results in Table 1 also show that the *Chrysanthemum indicum* extract prepared in Example 3 exhibits a significantly higher inhibitory effect on NF-κB nuclear translocation than the extract prepared in Example 2, and is also significantly higher than guaiacane-type sesquiterpene lactones with the structure shown in Formula (I) and the positive control drug dexamethasone; it has a very significant inhibitory effect on NF-κB nuclear translocation. This indicates that the *Chrysanthemum indicum* extract prepared by further eluting the *Chrysanthemum indicum* ODS using the liquid chromatography elution conditions of this invention can enrich a large amount of effective components that inhibit NF-κB nuclear translocation, and its inhibitory effect on NF-κB nuclear translocation is significantly higher than that of the *Chrysanthemum indicum* ODS elution fraction.
[0089] The experimental results in Table 1 also show that the inhibitory effect of the wild chrysanthemum extract prepared in Comparative Example 1 on NF-κB nuclear translocation is less than that of the wild chrysanthemum extract prepared in Example 2. While the inhibitory effect of the wild chrysanthemum extract prepared in Comparative Example 2 on NF-κB nuclear translocation is improved compared to that prepared in Example 2, the increase is not significant, and the improvement is far less than that of the wild chrysanthemum extract prepared in Example 3. This indicates that the liquid chromatography elution conditions in this invention are crucial. Only wild chrysanthemum extracts prepared under the liquid chromatography elution conditions of this invention can achieve a significantly improved inhibitory effect on NF-κB nuclear translocation compared to those prepared under the same conditions. Conversely, wild chrysanthemum extracts prepared under other liquid chromatography elution conditions do not show a significant or further improvement in the inhibitory effect on NF-κB nuclear translocation compared to those prepared under the same conditions.
Claims
1. The application of guaiacane-type sesquiterpene lactones in the preparation of drugs with inhibitory effects on NF-κB nuclear translocation; characterized in that, The guaiacol-type sesquiterpene lactone compound described above has the structure shown in formula (I): （Ⅰ）。 2. The application of guaiacol-type sesquiterpene lactones in the preparation of drugs for treating inflammatory diseases; characterized in that, The guaiacol-type sesquiterpene lactone compound described above has the structure shown in formula (I): （Ⅰ）。 3. The application according to claim 2, characterized in that, The inflammatory disease described is an inflammatory disease caused by NF-κB nuclear translocation.